https://digital.nhs.uk/data-and-information/publications/statistical/nhs-workforce-statistics<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"}
}
, "answeringMemberConstituency" : {"_value" : "Bristol South"}
, "answeringMemberPrinted" : {"_value" : "Karin Smyth"}
, "dateOfAnswer" : {"_value" : "2024-07-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-07-29T09:52:15.643Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-07-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Doctors and Nurses"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many (a) nurses and (b) doctors were employed by the NHS in (i) May 2010 and (ii) the most recent month for which data is available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4813", "label" : {"_value" : "Biography information for Mr Richard Holden"}
}
, "tablingMemberConstituency" : {"_value" : "Basildon and Billericay"}
, "tablingMemberPrinted" : [{"_value" : "Mr Richard Holden"}
], "uin" : "1577"}
, {"_about" : "http://data.parliament.uk/resources/1722822", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1722822/answer", "answerText" : {"_value" : "The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used in the treatment of cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe, and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints in producing the volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.<\/p>
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for\u202fCreon\u202f10,000 and 25,000 capsules to limit prescriptions to one months\u2019 supply, to allow demand management.<\/p>
We understand how frustrating and distressing medicine supply issues can be. While we can\u2019t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and to help mitigate risks to patients.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"}
}
, "answeringMemberConstituency" : {"_value" : "Bristol South"}
, "answeringMemberPrinted" : {"_value" : "Karin Smyth"}
, "dateOfAnswer" : {"_value" : "2024-07-26", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-07-26T08:59:36.517Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cystic Fibrosis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will take steps to ensure the supply of pancreatic enzyme replacement therapies for people with cystic fibrosis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/350", "label" : {"_value" : "Biography information for Sir John Hayes"}
}
, "tablingMemberConstituency" : {"_value" : "South Holland and The Deepings"}
, "tablingMemberPrinted" : [{"_value" : "Sir John Hayes"}
], "uin" : "1189"}
, {"_about" : "http://data.parliament.uk/resources/1722976", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1722976/answer", "answerText" : {"_value" : "
Insurers make commercial decisions about pricing and the terms of cover they offer based on their assessment of the relevant risks. This is usually informed by the insurer\u2019s claims experience and other industry-wide statistics. The respective capabilities of insurers to assess risk is a key element on which they compete, and the Government does not intend to intervene in these commercial decisions, as this could damage competition in the market. This competition is important and should lead to better products and lower prices for consumers overall.<\/p>
Price is an important factor on which insurers compete to win customers, and that competition should push insurers to continuously improve their assessment of risks in order to lower prices and create better products for consumers. The Government intervening in insurance markets could damage that competition and, therefore, we do not generally intervene in the commercial pricing decisions of insurers.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"}
}
, "answeringMemberConstituency" : {"_value" : "Bristol South"}
, "answeringMemberPrinted" : {"_value" : "Karin Smyth"}
, "dateOfAnswer" : {"_value" : "2024-07-26", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-07-26T08:18:15.98Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Health Insurance: Private Sector"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of fee setting and de-recognition procedures on the (a) cost and (b) availability of private medical insurance.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
}
, "tablingMemberConstituency" : {"_value" : "Christchurch"}
, "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
], "uin" : "1183"}
, {"_about" : "http://data.parliament.uk/resources/1723011", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1723011/answer", "answerText" : {"_value" : "
The Department, through the National Institute for Health and Care Research (NIHR), provides funding for research projects which aim to understand the underlying causes of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and find new treatments for the condition. For example, the NIHR, together with the Medical Research Council, have funded the world\u2019s largest genome-wide association study of ME/CFS. This £3.2 million study, termed DecodeME, will analyse samples from 25,000 people with ME/CFS to search for genetic differences that may indicate underlying causes or an increased risk of developing the condition. By helping us to understand ME/CFS better, this research has the potential to lead to new treatments for the condition.<\/p>
Integrated care boards (ICBs) are responsible for commissioning specialist ME/CFS services that meet the needs of their population, subject to local prioritisation and funding. The process of commissioning services should take into account best practice guidance such as the National Institute for Health and Care Excellence\u2019s (NICE) guidance on ME/CFS diagnosis and management, published in October 2021.<\/p>
It is the duty of clinicians to keep themselves appraised of best practice, in particular guidance issued by the NICE. Whilst guidelines are not mandatory, clinicians and commissioners are expected to take them fully into account when designing services to meet the needs of their local population. The NICE promotes its guidance via its website, newsletters, and other media.<\/p>
In October 2023, the British Association of Clinicians in ME/CFS published the ME/CFS National Services Survey. This report provides insight into the services being delivered for adults, children, and young people with ME/CFS.<\/p>
The Department has been working with NHS England to develop an e-learning course on ME/CFS for healthcare professionals, to support staff to be able to provide better care and improve patient outcomes. This has involved feedback and input from patients. The Medical Schools Council will promote the NHS England e-learning package on ME/CFS to all United Kingdom medical schools, and encourage medical schools to provide undergraduates with direct patient experience of ME/CFS. A decision on next steps on ME/CFS at the national level will be taken in the coming weeks.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
, "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
, "dateOfAnswer" : {"_value" : "2024-07-25", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-07-25T16:24:15.447Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Chronic Fatigue Syndrome: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve (a) diagnosis, (b) treatment and (c) awareness of Myalgic Encephalomyelitis (ME) in the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : "http://data.parliament.uk/members/5274", "tablingMemberConstituency" : {"_value" : "Dudley"}
, "tablingMemberPrinted" : [{"_value" : "Sonia Kumar"}
], "uin" : "1395"}
, {"_about" : "http://data.parliament.uk/resources/1723013", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1723013/answer", "answerText" : {"_value" : "
From September 2023, the routine shingles vaccination programme changed from the Zostavax vaccine to the more effective two dose Shingrix vaccine, to better protect individuals from the effects of shingles, provide better clinical outcomes, and reduce pressures on the health system. As a result, almost 1 million more people became eligible for the shingles vaccination.<\/p>
<\/p>
When a vaccination programme is expanded, decisions must be made regarding who to offer the vaccine to first. These decisions are based on advice given by the Joint Committee on Vaccination and Immunisation (JCVI), and include evidence on the impact of the vaccine in different age groups as well as the capacity of the National Health Service to deliver the vaccination programme alongside other important healthcare priorities.<\/p>
<\/p>
The expansion of the shingles programme currently includes those turning 65 years old on or after 1 September 2023, as well as those aged 50 years old and over who are at increased risk of serious complications. Phasing the roll-out of the shingles vaccination over time to everyone 60 years old and over is in line with the JCVI\u2019s recommendation and maximises cost effectiveness and population benefit, ensures consistent messaging over time to maximise coverage, and takes account of NHS capacity, all while being consistent with the approach taken by all four nations in the United Kingdom. This is a newly expanded programme and anyone unsure if they are eligible for the shingles vaccination should check online, on the NHS.UK website, or should speak to their general practice.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
, "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
, "dateOfAnswer" : {"_value" : "2024-07-26", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-07-26T13:35:29.053Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Shingles: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of offering shingles vaccines to everyone aged 60 and over.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : "http://data.parliament.uk/members/5075", "tablingMemberConstituency" : {"_value" : "Ealing Southall"}
, "tablingMemberPrinted" : [{"_value" : "Deirdre Costigan"}
], "uin" : "1397"}
, {"_about" : "http://data.parliament.uk/resources/1723041", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1723041/answer", "answerText" : {"_value" : "
The Government recognises that prevention will always be better, and cheaper, than a cure. We will take action to prevent and tackle the obesity crisis head on, creating the healthiest generation of children ever.<\/p>
As set out in the King\u2019s Speech, we are committed to implementing the advertising restrictions for less healthy food and drink. A 9:00pm television watershed and 24-hour ban on paid-for advertising of less healthy food and drink products are due to come into force on 1 October 2025. The Government is also committed to banning the sale of high-caffeine energy drinks to under-16-year-olds. We will also stop the targeting of school children by fast food outlets by empowering councils to block the development of new fast food shops outside schools.<\/p>
Officials in the Office for Health Improvement and Disparities Midlands Region work closely with local partners, including local authorities and the National Health Service, to support them with local initiatives to promote a healthy lifestyle and tackle obesity.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
, "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
, "dateOfAnswer" : {"_value" : "2024-07-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-07-29T09:04:39.027Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Obesity: Children"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle childhood obesity in Dudley.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : "http://data.parliament.uk/members/5274", "tablingMemberConstituency" : {"_value" : "Dudley"}
, "tablingMemberPrinted" : [{"_value" : "Sonia Kumar"}
], "uin" : "1425"}
, {"_about" : "http://data.parliament.uk/resources/1723068", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1723068/answer", "answerText" : {"_value" : "
The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used in the treatment of cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe, and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints in producing the volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.<\/p>
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for\u202fCreon\u202f10,000 and 25,000 capsules to limit prescriptions to one months\u2019 supply, to allow demand management.<\/p>
We understand how frustrating and distressing medicine supply issues can be. While we can\u2019t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and to help mitigate risks to patients.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"}
}
, "answeringMemberConstituency" : {"_value" : "Bristol South"}
, "answeringMemberPrinted" : {"_value" : "Karin Smyth"}
, "dateOfAnswer" : {"_value" : "2024-07-26", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-07-26T08:52:51.24Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pancreatin"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the supply of Creon.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : "http://data.parliament.uk/members/5109", "tablingMemberConstituency" : {"_value" : "Redditch"}
, "tablingMemberPrinted" : [{"_value" : "Chris Bloore"}
], "uin" : "1452"}
, {"_about" : "http://data.parliament.uk/resources/1723093", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1723093/answer", "answerText" : {"_value" : "
The Government is considering the recommendations of The Hughes Report, and to prevent future harm, the Medicines and Healthcare products Regulatory Agency, NHS England, and others have taken action to strengthen oversight of valproate prescribing and mesh procedures. For example, nine specialist mesh centres are in operation across England, ensuring that women with complications of mesh inserted for urinary incontinence and vaginal prolapse get the right support in every region, and we have maintained the national pause on the use of pelvic mesh, which has been in place since July 2018.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/347", "label" : {"_value" : "Biography information for Baroness Merron"}
}
, "answeringMemberPrinted" : {"_value" : "Baroness Merron"}
, "dateOfAnswer" : {"_value" : "2024-07-26", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-07-26T12:34:40.16Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Sodium Valproate and Surgical Mesh Implants: Compensation"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask His Majesty's Government what assessment they have made of the recommendations of England\u2019s Patient Safety Commissioner in the 'Hughes Report' on the sodium valproate and mesh implant scandals; when they intend to respond to that report; and when they anticipate the first payments arising under the recommended redress scheme may be made.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4909", "label" : {"_value" : "Biography information for Lord Kamall"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Kamall"}
], "uin" : "HL259"}
, {"_about" : "http://data.parliament.uk/resources/1722436", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1722436/answer", "answerText" : {"_value" : "
A recently published YouScreen study provides evidence on offering a self-sampling test to non-attenders in the NHS Cervical Screening Programme. The UK National Screening Committee (UK NSC) plans to review this evidence and make a recommendation by the end of the year.<\/p>
In addition, an in-service evaluation is being commissioned by the National Institute for Health and Care Research to determine whether self-sampling could be offered as an option to everyone eligible for cervical screening. The findings from this evaluation will be used to inform any recommendations made by the UK NSC.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
, "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
, "dateOfAnswer" : {"_value" : "2024-07-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-07-24T09:44:09.64Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-07-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cervical Cancer: Screening"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to roll-out self-sampling cervical cancer tests.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "953"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=1&min-answer.questionFirstAnswered.=2024-03-26T17%3A59%3A34.637Z", "page" : 0, "startIndex" : 1, "totalResults" : 1500, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}